Vasopressin

ABSTRACT

Vasopressin is a hormone that is essential for both osmotic and cardiovascular homeostasis. A deficiency of vasopressin exists in some shock states and replacement of physiological levels of vasopressin can restore vascular tone. Vasopressin is therefore emerging as a rational therapy for vasodilatory shock. In this article we review the rationale and summarize the evidence for using vasopressin in vasodilatory shock states, such as septic shock. We then highlight the areas of uncertainty in using vasopressin for septic shock and summarize the reasons for clinical equipoise. We close by suggesting that further randomized controlled trials of vasopressin in septic shock are required before vasopressin is used routinely for management of septic shock.

KEYWORDS

Vasopressins - sepsis syndrome - shock - septic - antidiurectic hormone - receptors

REFERENCES

• 1 Holmes C L, Patel B M, Russell J A, Walley K R. Physiology of vasopressin relevant to management of septic shock.  Chest. 2001;  120 989-1002
• 2 Landry D W, Oliver J A. The pathogenesis of vasodilatory shock.  N Engl J Med. 2001;  345 588-595
• 3 Oliver H, Schaefer E A. On the physiological action of extracts of the pituitary body and certain other glandular organs.  J Physiol. 1895;  18 277-279
• 4 von den Velden R. Die nierenwirkung von hypophysenextrakten beim menshen.  Berl Klin Wochenschr. 1913;  50 2083-2086
• 5 Verney E B. The antidiuretic hormone and the factor which determines its release.  Proc R Soc Lond B Biol Sci. 1947;  135 25-106
• 6 Laszlo F A, Laszlo Jr F, De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists.  Pharmacol Rev. 1991;  43 73-108
• 7 Turner R A, Pierce J G, Du Vigneaud V. The purification and the amino acid content of vasopressin preparation.  J Biol Chem. 1951;  191 21
• 8 Du Vigneaud V, Gash D T, Katsoyannis P G. A synthetic preparation possessing biological properties associated with arginine-vasopressin.  J Am Chem Soc. 1954;  76 4751-4752
• 9 Goetz K L, Bond G C, Smith W E. Effect of moderate hemorrhage in humans on plasma ADH and renin.  Proc Soc Exp Biol Med. 1974;  145 277-280
• 10 Wilson M F, Brackett D J, Tompkins P, Benjamin B, Archer L T, Hinshaw L B. Elevated plasma vasopressin concentrations during endotoxin and E. coli shock.  Adv Shock Res. 1981;  6 15-26
• 11 Morales D, Madigan J, Cullinane S et al.. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock.  Circulation. 1999;  100 226-229
• 12 Errington M L, Rocha e Silva Jr M. The secretion and clearance of vasopressin during the development of irreversible haemorrhagic shock.  J Physiol. 1971;  217 43P-45P
• 13 Sharshar T, Blanchard A, Paillard M, Raphael J C, Gajdos P, Annane D. Circulating vasopressin levels in septic shock.  Crit Care Med. 2003;  31 1752-1758
• 14 Reid I A. Role of vasopressin deficiency in the vasodilation of septic shock.  Circulation. 1997;  95 1108-1110
• 15 Sharshar T, Carlier R, Blanchard A et al.. Depletion of neurohypophyseal content of vasopressin in septic shock.  Crit Care Med. 2002;  30 497-500
• 16 Garrard C S, Kontoyannis D A, Piepoli M. Spectral analysis of heart rate variability in the sepsis syndrome.  Clin Auton Res. 1993;  3 5-13
• 17 Zerbe R L, Henry D P, Robertson G L. Vasopressin response to orthostatic hypotension: etiologic and clinical implications.  Am J Med. 1983;  74 265-271
• 18 Landry D W, Levin H R, Gallant E M et al.. Vasopressin deficiency contributes to the vasodilation of septic shock.  Circulation. 1997;  95 1122-1125
• 19 Day T A, Randle J C, Renaud L P. Opposing alpha- and beta-adrenergic mechanisms mediate dose-dependent actions of noradrenaline on supraoptic vasopressin neurones in vivo.  Brain Res. 1985;  358 171-179
• 20 Holmes C L, Granton J T, Landry D W. Science review: vasopressin and the cardiovascular system part 2-clinical physiology.  Crit Care. 2004;  8 15-23
• 20a Thibonnier M, Coles P, Thibonnier A, Shoham M. Molecular pharmacology and modeling of vasopressin receptors.  Prog Brain Res. 2002;  139 179-196
• 21 Wakatsuki T, Nakaya Y, Inoue I. Vasopressin modulates K(+)-channel activities of cultured smooth muscle cells from porcine coronary artery.  Am J Physiol. 1992;  263(2 Pt 2) H491-H496
• 22 Landry D W, Oliver J A. The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog.  J Clin Invest. 1992;  89 2071-2074
• 23 Geisen K, Vegh A, Krause E, Papp J G. Cardiovascular effects of conventional sulfonylureas and glimepiride.  Horm Metab Res. 1996;  28 496-507
• 24 Gardiner S M, Kemp P A, March J E, Bennett T. Regional haemodynamic responses to infusion of lipopolysaccharide in conscious rats: effects of pre- or post-treatment with glibenclamide.  Br J Pharmacol. 1999;  128 1772-1778
• 25 Salzman A L, Vromen A, Denenberg A, Szabo C. K(ATP)-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock.  Am J Physiol. 1997;  272 (2 Pt 2) H688-H694
• 26 Bolotina V M, Najibi S, Palacino J J, Pagano P J, Cohen R A. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle.  Nature. 1994;  368 850-853
• 27 Archer S L, Huang J M, Hampl V, Nelson D P, Shultz P J, Weir E K. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase.  Proc Natl Acad Sci USA. 1994;  91 7583-7587
• 28 Kilbourn R. Nitric oxide synthase inhibitors: a mechanism-based treatment of septic shock.  Crit Care Med. 1999;  27 857-858
• 29 Umino T, Kusano E, Muto S et al.. AVP inhibits LPS- and IL-1beta-stimulated NO and cGMP via V1 receptor in cultured rat mesangial cells.  Am J Physiol. 1999;  276(3 Pt 2) F433-F441
• 30 Karmazyn M, Manku M S, Horrobin D F. Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins.  Endocrinology. 1978;  102 1230-1236
• 31 Noguera I, Medina P, Segarra G et al.. Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery.  Br J Pharmacol. 1997;  122 431-438
• 32 Emori T, Hirata Y, Ohta K et al.. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin.  Hypertension. 1991;  18 165-170
• 33 Caramelo C, Okada K, Tsai P, Linas S L, Schrier R W. Interaction of arginine vasopressin and angiotensin II on Ca2+ in vascular smooth muscle cells.  Kidney Int. 1990;  38 47-54
• 34 Iversen B M, Arendshorst W J. ANG II and vasopressin stimulate calcium entry in dispersed smooth muscle cells of preglomerular arterioles.  Am J Physiol. 1998;  274(3 Pt 2) F498-F508
• 34a Thibonnier M, Conarty D M, Preston J A, Wilkins P L, Berti-Mattera L N, Mattera R. Molecular pharmacology of human vasopressin receptors.  Adv Exp Med Biol. 1998;  449 251-276
• 35 Holmes C L, Landry D W, Granton J T. Science review: vasopressin and the cardiovascular system, I: Receptor physiology.  Crit Care. 2003;  7 427-434
• 36 Walker B R, Haynes Jr J, Wang H L, Voelkel N F. Vasopressin-induced pulmonary vasodilation in rats.  Am J Physiol. 1989;  257(2 Pt 2) H415-H422
• 37 Eichinger M R, Russ R D, Walker B R. Potassium channels are not involved in vasopressin-induced vasodilation in the rat lung.  Am J Physiol. 1994;  266(2 Pt 2) H491-H495
• 38 Russ R D, Walker B R. Role of nitric oxide in vasopressinergic pulmonary vasodilatation.  Am J Physiol. 1992;  262(3 Pt 2) H743-H747
• 39 Evora P R, Pearson P J, Schaff H V. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery: V1-receptor-mediated production of nitric oxide.  Chest. 1993;  103 1241-1245
• 40 Suzuki Y, Satoh S, Oyama H, Takayasu M, Shibuya M. Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo.  Stroke. 1993;  24 1049-1053: , discussion 1053-1044
• 41 Vanhoutte P M, Katusic Z S, Shepherd J T. Vasopressin induces endothelium-dependent relaxations of cerebral and coronary, but not of systemic arteries.  J Hypertens Suppl. 1984;  2 S421-S422
• 42 Oyama H, Suzuki Y, Satoh S et al.. Role of nitric oxide in the cerebral vasodilatory responses to vasopressin and oxytocin in dogs.  J Cereb Blood Flow Metab. 1993;  13 285-290
• 43 Rudichenko V M, Beierwaltes W H. Arginine vasopressin-induced renal vasodilation mediated by nitric oxide.  J Vasc Res. 1995;  32 100-105
• 44 Tamaki T, Kiyomoto K, He H et al.. Vasodilation induced by vasopressin V2 receptor stimulation in afferent arterioles.  Kidney Int. 1996;  49 722-729
• 45 Okamura T, Ayajiki K, Fujioka H, Toda N. Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries.  J Hypertens. 1999;  17 673-678
• 46 Rapps J A, Jones A W, Sturek M, Magliola L, Parker J L. Mechanisms of altered contractile responses to vasopressin and endothelin in canine coronary collateral arteries.  Circulation. 1997;  95 231-239
• 47 Thibonnier M, Conarty D M, Preston J A, Plesnicher C L, Dweik R A, Erzurum S C. Human vascular endothelial cells express oxytocin receptors.  Endocrinology. 1999;  140 1301-1309
• 48 Holmes C L, Walley K R, Chittock D R, Lehman T, Russell J A. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series.  Intensive Care Med. 2001;  27 1416-1421
• 49 Patel B M, Chittock D R, Russell J A, Walley K R. Beneficial effects of short-term vasopressin infusion during severe septic shock.  Anesthesiology. 2002;  96 576-582
• 50 Landry D W, Levin H R, Gallant E M et al.. Vasopressin pressor hypersensitivity in vasodilatory septic shock.  Crit Care Med. 1997;  25 1279-1282
• 51 Malay M B, Ashton Jr R C, Landry D W, Townsend R N. Low-dose vasopressin in the treatment of vasodilatory septic shock.  J Trauma. 1999;  47 699-703: , discussion 703-695
• 52 Argenziano M, Choudhri A F, Oz M C, Rose E A, Smith C R, Landry D W. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement.  Circulation. 1997;  96(9 Suppl) II-286-290
• 53 Argenziano M, Chen J M, Choudhri A F et al.. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent.  J Thorac Cardiovasc Surg. 1998;  116 973-980
• 54 Argenziano M, Chen J M, Cullinane S et al.. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation.  J Heart Lung Transplant. 1999;  18 814-817
• 55 Rosenzweig E B, Starc T J, Chen J M et al.. Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery.  Circulation. 1999;  100(19 Suppl) II182-II186
• 56 Morales D L, Gregg D, Helman D N et al.. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock.  Ann Thorac Surg. 2000;  69 102-106
• 57 Chen J M, Cullinane S, Spanier T B et al.. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors.  Circulation. 1999;  100(19 Suppl) II244-II246
• 58 Gold J A, Cullinane S, Chen J, Oz M C, Oliver J A, Landry D W. Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension.  Crit Care Med. 2000;  28 249-252
• 59 Dünser M W, Mayr A J, Ulmer H et al.. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis.  Anesth Analg. 2001;  93 7-13
• 60 Dünser M W, Mayr A J, Stallinger A et al.. Cardiac performance during vasopressin infusion in postcardiotomy shock.  Intensive Care Med. 2002;  28 746-751
• 60a Gold J, Cullinane S, Chen J et al.. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.  Am J Cardiol. 2000;  85 506-508, , A511
• 61 Cowley Jr A W, Cushman W C, Quillen Jr E W, Skelton M M, Langford H G. Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake.  Hypertension. 1981;  3(3 Pt 2) I93-100
• 62 Dünser M W, Mayr A J, Tur A et al.. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors.  Crit Care Med. 2003;  31 1394-1398
• 63 Klinzing S, Simon M, Reinhart K, Bredle D L, Meier-Hellmann A. High-dose vasopressin is not superior to norepinephrine in septic shock.  Crit Care Med. 2003;  31 2646-2650
• 64 Dubois M J, De Backer D, Creteur J, Anane S, Vincent J L. Effect of vasopressin on sublingual microcirculation in a patient with distributive shock.  Intensive Care Med. 2003;  29 1020-1023
• 65 Sun Q, Dimopoulos G, Nguyen D N et al.. Low-dose vasopressin in the treatment of septic shock in sheep.  Am J Respir Crit Care Med. 2003;  168 481-486
• 66 Nasraway S A. Norepinephrine: no more “leave ’em dead”?.  Crit Care Med. 2000;  28 3096-3098
• 67 Avontuur J A, Tutein Nolthenius R P, Buijk S L, Kanhai K J, Bruining H A. Effect of L-NAME, an inhibitor of nitric oxide synthesis, on cardiopulmonary function in human septic shock.  Chest. 1998;  113 1640-1646
• 68 Avontuur J A, Tutein Nolthenius R P, van Bodegom J W, Bruining H A. Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study.  Crit Care Med. 1998;  26 660-667
• 69 Grover R, Zaccardelli D, Colice G, Guntupalli K, Watson D, Vincent J L. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group.  Crit Care Med. 1999;  27 913-922
• 70 Cobb J P. Use of nitric oxide synthase inhibitors to treat septic shock: the light has changed from yellow to red.  Crit Care Med. 1999;  27 855-856
• 71 Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J KR. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group.  Lancet. 2000;  356 2139-2143
• 72 Holmes C L, Walley K R. Bad medicine: low-dose dopamine in the ICU.  Chest. 2003;  123 1266-1275